TTP 273

Drug Profile

TTP 273

Alternative Names: TTP-273

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator vTv Therapeutics
  • Developer vTv Therapeutics LLC
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 14 Dec 2016 Topline efficacy and adverse events data from a phase II trial in Type-2 diabetes mellitus released by vTv Therapeutics
  • 16 Aug 2016 vTv Therapeutics completes enrolment in the phase II LOGRA trial for Type-2 diabetes mellitus in USA
  • 22 Feb 2016 Pharmacodynamics data from preclinical studies in Type-2 diabetes mellitus released by vTv Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top